Table 3 Summary of events in the two groups.

From: Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

 

C-HD

E-HD

Observation vintage (patientyear)

467

544

Number of Primary events

50

41

(all causes of deaths and non-lethal CVD events)

 Cardiac events including death

29

20

  Congestive heart failure

11

8

  Ischemic heart disease

13

9

  Aortic aneurysm rupture

1

1

  Sudden cardiac arrest

4

2

 Apoplexy including death (bleeding/infarction)

6 (1/5)

10 (2/8)

 PAD including death

8

2

Primary events rate (1000 patients·year: 95%CI)

107.1 (81.2–141.1)

75.4 (55.6–102.2)

Number of deaths

17

20

Deaths rate (1000 patients·year: 95%CI)

36.4 (22.7–58.3)

36.8 (23.8–56.8)

  1. C-HD, conventional haemodialysis; E-HD, electrolyzed water haemodialysis.
  2. PAD, peripheral artery disease (with surgical procedure).